Ruxience (rituximab) is a biologic medicine that treats the pain and swelling of arthritis by suppressing part of the body's immune system.
Ruxience destroys a type of white blood cell that has a role in the body's immune system called the B-cell.
Ruxience can help in the treatment of a wide variety of diseases including rheumatoid arthritis and other autoimmune diseases, some types of cancer, and ultimately any disease that involves unwanted activity from B-cells. Ruxience is also used to help prevent tissue rejection in organ transplant patients.
Ruxience is available as an intravenous (IV) infusion.
Some patients feel better soon after receiving the medication, but in others, it can take longer: up to 3 or 4 months.
The manufacturer of Ruxience offers a support program to Canadian patients that are prescribed the medication:Patient support program enrolment forms
Important Tests and Risks
Watch Canadian rheumatologist Dr. Andy Thompson introduce Ruxience.
Watch Canadian rheumatologist Dr. Angèle Turcotte introduce Ruxience.
Drug Identification Number (DIN)